Company news

BioXcel Therapeutics, Inc. news in 2024

BioXcel Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

November 21, 2024

BioXcel Therapeutics Announces Proposed Public Offering

November 20, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

November 13, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

November 11, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

November 7, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

October 28, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

October 14, 2024

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

September 18, 2024

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

September 4, 2024

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

August 6, 2024

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

August 5, 2024

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

July 29, 2024

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

July 15, 2024

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

June 24, 2024

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 27, 2024

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 20, 2024

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

May 8, 2024

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

April 24, 2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

April 23, 2024

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

April 21, 2024

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

April 9, 2024

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

March 24, 2024

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

March 14, 2024

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

March 11, 2024

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

February 29, 2024

BioXcel Therapeutics Announces Termination of Proposed Public Offering

February 12, 2024

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

February 11, 2024

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

February 5, 2024

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

February 4, 2024

Calls in 2024

Decks in 2024